Trial Profile
Safety and pharmacokinetics study of high-dose, once-daily raltegravir in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2015
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck & Co
- 10 Apr 2015 New trial record